Dr. Randolph on Future Treatment Approaches in Thyroid Cancer

Gregory W. Randolph, MD
Published: Monday, Oct 10, 2016


Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts General Hospital, discusses future methods of treating patients with thyroid cancer.

Individual subsets of thyroid cancer are beginning to be discovered as indolent disease, Randolph explains. These include microcarcinomas, NIFTP lesions, and smaller tumors without nodal disease. These clinical parameters will be made more robust via a better understanding of the genomic makeup of these lesions.

Less aggressive treatment can then be given to patients who have a disease that is biologically understood to be a more indolent course, Randolph adds.

Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts General Hospital, discusses future methods of treating patients with thyroid cancer.

Individual subsets of thyroid cancer are beginning to be discovered as indolent disease, Randolph explains. These include microcarcinomas, NIFTP lesions, and smaller tumors without nodal disease. These clinical parameters will be made more robust via a better understanding of the genomic makeup of these lesions.

Less aggressive treatment can then be given to patients who have a disease that is biologically understood to be a more indolent course, Randolph adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x